-+ 0.00%
-+ 0.00%
-+ 0.00%

Passage Bio posts corporate presentation on PBFT02 gene therapy for frontotemporal dementia

PUBT·04/20/2026 11:07:35
Listen to the news
Passage Bio posts corporate presentation on PBFT02 gene therapy for frontotemporal dementia
  • Passage Bio highlighted PBFT02 as a one-time AAV1 gene therapy for FTD-GRN delivered via intra-cisterna magna injection.
  • Interim data showed CSF progranulin durability to 18 months at dose 1, with mean CSF progranulin 22.8 ng/mL at 12 months (n=6).
  • Volumetric MRI analysis in CDR 1 patients showed 64% reduction in whole-brain atrophy at 12 months versus natural history, with 54% reduction in frontotemporal cortex atrophy.
  • Safety update showed PBFT02 generally well tolerated as of March 23, 2026, with 2 serious treatment-emergent adverse events related to PBFT02 totaling 3 events.
  • Passage Bio projected cash runway through 1Q 2027 based on cash, cash equivalents, and marketable securities as of Dec. 31, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.